Literature DB >> 24221341

Staging of acute exacerbation in patients with idiopathic pulmonary fibrosis.

Tomoo Kishaba1, Hitoshi Tamaki, Yousuke Shimaoka, Hajime Fukuyama, Shin Yamashiro.   

Abstract

BACKGROUND: The purpose of this study was to evaluate the predictors of a 3-month mortality rate of acute exacerbation of idiopathic pulmonary fibrosis (IPF) and provide a new staging system.
METHODS: A total of 594 patients with IPF were included in this retrospective, observational study conducted from January 2001 to December 2010 at Okinawa Chubu Hospital.
RESULTS: Among the 594 patients, 58 (9.8 %) developed acute exacerbation (AE) of IPF during the 10-year observation period. The median follow-up period for AE was 10.4 months. In-hospital mortality was 56.9 % and the 3-month mortality rate was 63.8 %. We identified the following four parameters in a multivariate analysis as: serum lactate dehydrogenase, sialylated carbohydrate antigen (KL-6), ratio of partial pressure of oxygen and fraction of inspiratory oxygen, and total extent of abnormal findings on high-resolution computed tomography of the chest. Patients were divided into two groups on the basis of the four composite parameters. Patients in the extensive disease-stage group required more mechanical ventilation and intensive therapy than those in the limited disease-stage group. The 3-month mortality rate was higher in patients in the extensive disease-stage group than in patients in the limited disease-stage group (80.6 vs. 54.5 %, respectively; p = 0.007).
CONCLUSIONS: Staging of AE in patients with IPF provided useful information regarding disease severity and short-term outcome.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24221341     DOI: 10.1007/s00408-013-9530-0

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  28 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Idiopathic interstitial pneumonias: diagnostic accuracy of thin-section CT in 129 patients.

Authors:  T Johkoh; N L Müller; Y Cartier; P V Kavanagh; T E Hartman; M Akira; K Ichikado; M Ando; H Nakamura
Journal:  Radiology       Date:  1999-05       Impact factor: 11.105

3.  Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.

Authors:  Roland M du Bois; Derek Weycker; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Alex Kartashov; Talmadge E King; Lisa Lancaster; Paul W Noble; Steven A Sahn; Michiel Thomeer; Dominique Valeyre; Athol U Wells
Journal:  Am J Respir Crit Care Med       Date:  2011-09-22       Impact factor: 21.405

4.  Fleischner Society: glossary of terms for thoracic imaging.

Authors:  David M Hansell; Alexander A Bankier; Heber MacMahon; Theresa C McLoud; Nestor L Müller; Jacques Remy
Journal:  Radiology       Date:  2008-01-14       Impact factor: 11.105

5.  An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease.

Authors:  Keith C Meyer; Ganesh Raghu; Robert P Baughman; Kevin K Brown; Ulrich Costabel; Roland M du Bois; Marjolein Drent; Patricia L Haslam; Dong Soon Kim; Sonoko Nagai; Paola Rottoli; Cesare Saltini; Moisés Selman; Charlie Strange; Brent Wood
Journal:  Am J Respir Crit Care Med       Date:  2012-05-01       Impact factor: 21.405

6.  Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure.

Authors:  J B Stern; H Mal; O Groussard; O Brugière; A Marceau; G Jebrak; M Fournier
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

Review 7.  Clinical course and prediction of survival in idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Harold R Collard; Talmadge E King
Journal:  Am J Respir Crit Care Med       Date:  2010-10-08       Impact factor: 21.405

8.  Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease.

Authors:  J C Bestall; E A Paul; R Garrod; R Garnham; P W Jones; J A Wedzicha
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

9.  Idiopathic pulmonary fibrosis: progression of honeycombing at thin-section CT.

Authors:  M Akira; M Sakatani; E Ueda
Journal:  Radiology       Date:  1993-12       Impact factor: 11.105

10.  Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival.

Authors:  Hiromitsu Sumikawa; Takeshi Johkoh; Thomas V Colby; Kazuya Ichikado; Moritaka Suga; Hiroyuki Taniguchi; Yasuhiro Kondoh; Takashi Ogura; Hiroaki Arakawa; Kiminori Fujimoto; Atsuo Inoue; Naoki Mihara; Osamu Honda; Noriyuki Tomiyama; Hironobu Nakamura; Nestor L Müller
Journal:  Am J Respir Crit Care Med       Date:  2007-11-01       Impact factor: 21.405

View more
  53 in total

1.  Staging and outcome in acute exacerbation of idiopathic pulmonary fibrosis: are all limits and determinants under control?

Authors:  Antonio M Esquinas; Alejandro Ubeda Iglesias; Angela Reina González
Journal:  Lung       Date:  2014-10-14       Impact factor: 2.584

2.  [Acute on chronic respiratory failure in interstitial pneumonias].

Authors:  M Westhoff
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-08-16       Impact factor: 0.840

Review 3.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis.

Authors:  Tomoo Kishaba
Journal:  Eurasian J Med       Date:  2017-10

4.  What factors determine the survival of patients with an acute exacerbation of interstitial lung disease after lung cancer resection?

Authors:  Masahiro Miyajima; Atsushi Watanabe; Toshihiko Sato; Satoshi Teramukai; Masahito Ebina; Kazuma Kishi; Yukihiko Sugiyama; Haruhiko Kondo; Satoru Kobayashi; Yutaka Takahashi; Hiroyuki Ito; Ryoji Yamamoto; Shigeki Sawada; Hideki Fujimori; Kazunori Okabe; Jun Arikura; Yasushi Shintani; Hiroshige Nakamura; Shinichi Toyooka; Tohru Hasumi; Takehiro Watanabe; Yoshinobu Hata; Hisashi Iwata; Minoru Aoki; Kazuhito Funai; Shuhei Inoue; Osamu Kawashima; Tomohiko Iida; Hiroshi Date
Journal:  Surg Today       Date:  2017-11-09       Impact factor: 2.549

Review 5.  Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies.

Authors:  Maya M Juarez; Andrew L Chan; Andrew G Norris; Brian M Morrissey; Timothy E Albertson
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

6.  Clinical characteristics of idiopathic pulmonary fibrosis patients with gender, age, and physiology staging at Okinawa Chubu Hospital.

Authors:  Tomoo Kishaba; Yousuke Shimaoka; Hajime Fukuyama; Hiroaki Nagano; Yuichiro Nei; Shin Yamashiro; Hitoshi Tamaki
Journal:  J Thorac Dis       Date:  2015-05       Impact factor: 2.895

7.  Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status.

Authors:  Tomoo Kishaba; Hiroaki Nagano; Yuichiro Nei; Shin Yamashiro
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

8.  Clinical significance of Charlson comorbidity index as a prognostic parameter for patients with acute or subacute idiopathic interstitial pneumonias and acute exacerbation of collagen vascular diseases-related interstitial pneumonia.

Authors:  Kota Murohashi; Yu Hara; Yusuke Saigusa; Nobuaki Kobayashi; Takashi Sato; Masaki Yamamoto; Makoto Kudo; Takeshi Kaneko
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

9.  Clinical Characteristics Based on the New Criteria of Acute Exacerbation in Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Tomoo Kishaba; Yuichiro Nei; Masashi Momose; Hiroaki Nagano; Shin Yamashiro
Journal:  Eurasian J Med       Date:  2018-02-01

10.  Acute exacerbation of idiopathic pulmonary fibrosis: who to treat, how to treat.

Authors:  Tejaswini Kulkarni; Steven R Duncan
Journal:  Curr Pulmonol Rep       Date:  2019-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.